Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)
China flag China · Delayed Price · Currency is CNY
17.39
-0.43 (-2.41%)
Nov 17, 2026, 3:04 PM CST

SHE:300255 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
913.35858.2997.771,3972,3272,941
Other Revenue
16.9316.9333.0413.259.6527.3
930.28875.131,0311,4102,3362,968
Revenue Growth
0.24%-15.10%-26.92%-39.63%-21.29%25.56%
Cost of Revenue
852.35854.27937.351,7331,3151,246
Gross Profit
77.9320.8693.46-322.771,0211,722
Selling, General & Admin
191.41183.87216.34630.71739.691,220
Research & Development
33.5734.0847.19158.82145.01150.63
Other Operating Expenses
7.089.462.1117.2422.0226.77
Operating Expenses
267.86256.94272.24822.15913.231,398
Operating Income
-189.93-236.07-178.78-1,145107.99324.06
Interest Expense
-104.86-96.91-102.83-96.41-93.04-62.29
Interest & Investment Income
1.113.637.021.851.991.3
Currency Exchange Gain (Loss)
5.245.240.254.766.69-4.4
Other Non Operating Income (Expenses)
-36.17-27.26-15.36-13.67-12.8-10.13
EBT Excluding Unusual Items
-324.62-351.39-259.7-1,24810.84248.54
Impairment of Goodwill
----1.78-1.78-
Gain (Loss) on Sale of Assets
-0.25-0.23-0.78-0-0.09-0.11
Asset Writedown
-14.74-3.68-1.3--0.27-
Other Unusual Items
-0.68-0.594.718.499.4111.98
Pretax Income
-340.28-355.89-257.08-1,23218.12260.41
Income Tax Expense
16.3511.576.9516.467.9629.15
Earnings From Continuing Operations
-356.63-367.46-264.03-1,24810.16231.26
Minority Interest in Earnings
5.659.5714.557.947.362.31
Net Income
-350.97-357.9-249.48-1,24017.51233.57
Net Income to Common
-350.97-357.9-249.48-1,24017.51233.57
Net Income Growth
-----92.50%-7.62%
Shares Outstanding (Basic)
956918924919876934
Shares Outstanding (Diluted)
956918924919876934
Shares Change
-8.91%-0.68%0.58%4.91%-6.27%-0.23%
EPS (Basic)
-0.37-0.39-0.27-1.350.020.25
EPS (Diluted)
-0.37-0.39-0.27-1.350.020.25
EPS Growth
-----92.00%-7.41%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-177.14-67.68-183.37-205.6-428.1-305.21
Free Cash Flow Per Share
-0.18-0.07-0.20-0.22-0.49-0.33
Dividend Per Share
----0.0050.026
Dividend Growth
-----80.77%-
Gross Margin
8.38%2.38%9.07%-22.88%43.71%58.01%
Operating Margin
-20.42%-26.98%-17.34%-81.17%4.62%10.92%
Profit Margin
-37.73%-40.90%-24.20%-87.93%0.75%7.87%
Free Cash Flow Margin
-19.04%-7.73%-17.79%-14.58%-18.32%-10.28%
EBITDA
-126.48-168.81-106.43-1,071164.93379.86
EBITDA Margin
-13.60%-19.29%-10.32%-75.90%7.06%12.80%
D&A For EBITDA
63.4567.2672.3574.3956.9455.8
EBIT
-189.93-236.07-178.78-1,145107.99324.06
EBIT Margin
-20.42%-26.98%-17.34%-81.17%4.62%10.92%
Effective Tax Rate
----43.94%11.19%
Revenue as Reported
930.28875.131,0311,4102,3362,968